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Abstract
Background: Ehlers Danlos Syndrome is a rare form of inherited connective tissue disorder, which primarily affects
skin, joints, muscle, and blood cells. The current study aimed at finding the mutation that causing EDS type VII C
also known as “Dermatosparaxis” in this family.
Methods: Through systematic data querying of the electronic medical records (EMRs) of over 80,000 individuals,
we recently identified an EDS family that indicate an autosomal dominant inheritance. The family was consented
for genomic analysis of their de-identified data. After a negative screen for known mutations, we performed whole
genome sequencing on the male proband, his affected father, and unaffected mother. We filtered the list of non-
synonymous variants that are common between the affected individuals.
Results: The analysis of non-synonymous variants lead to identifying a novel mutation in the ADAMTSL2 (p. Gly421Ser)
gene in the affected individuals. Sanger sequencing confirmed the mutation.
Conclusion: Our work is significant not only because it sheds new light on the pathophysiology of EDS for
the affected family and the field at large, but also because it demonstrates the utility of unbiased large-scale
clinical recruitment in deciphering the genetic etiology of rare mendelian diseases. With unbiased large-scale
clinical recruitment we strive to sequence as many rare mendelian diseases as possible, and this work in EDS
serves as a successful proof of concept to that effect.
Keywords: Whole genome sequencing, Ehlers-Danlos Syndrome, Biorepository, Electronic medical records,
EDS, EMR, WGS
Background
Ehlers Danlos Syndrome (EDS) describes a group of her-
itable disorders where collagen synthesis and fibril for-
mation is disrupted. It affects approximately 1 in 5000 to
1 in 100,000 individuals, depending on subtype [1, 2].
Predominant phenotypes include articular hypermobility,
lax joints, and fragile tissue, skin, and blood vessels. EDS
can be extremely debilitating, requiring preventative and
protective measures from birth or onset of symptoms. A
large number of subtypes have been described, including
six major classifications: 1) Classical (Types I&II); 2)
Hypermobile (Type III); 3) Vascular (Type IV); 4)
Kyphoscoliosic (Type VI); 5) Arthrochalasic (Type VIIA
&VIIB); and 6) Dermatosparaxic (Type VIIC) [3]. These
can be transmitted through autosomal dominant, auto-
somal recessive, or x-linked inheritance. Mutations in a
number of genes involved in collagen synthesis have
been associated with different EDS subtypes, including
COL1A1, COL1A2, COL5A1, COL5A2 [2, 3], and
ADAMTS2 21. All EDS Type VIIC mutations identified
to date have been autosomal recessive. Here, we report
on an EDS patient, with symptomology that includes
dermatosparaxis (literally, “tearing of the skin”), which
is characteristic of EDS Type VIIC.
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Methods
Recruitment
The proband (and sister) were recruited at The Center
for Applied Genomics at The Children’s Hospital of
Philadelphia under a large-scale clinical recruitment pro-
ject, A Study of the Genetic Causes of Complex Pediatric
Disorders, aimed at recruiting over 100,000 Children
with both common and rare medical disorders. This
study was approved by the institutional review board of
The Children’s Hospital of Philadelphia. The proband
and his family members consented to release of de-
identified medical and genomic information for publica-
tion. For the proband and sister, this was in the form of
parental consent. All study participants blood was drawn
when they presented for a clinic visit. They consented to
prospective genomic analysis and analysis of electronic
medical records (EMRs). Recruitment was not targeted,
and the patients came to our attention through system-
atic data querying of de-identified EMR records from
over 80,000 individuals recruited over the last six years.
Cross-referencing our biorepository with rare-disease
codes (as defined by Online Mendelian Inheritance in
Man (OMIM) code 225410 and International Statistical
Classification of Diseases and Related Health Problems 9
(ICD9) code 756.83), we identified the EDS proband
who had longitudinal EMRs that included a detailed
family history and relatively extensive medical history of
both parents.
EMR querying
Our broad consent protocol includes extraction of DNA,
blood/sera, access to EMRs, and the permission to per-
form a wide range of genomic studies in consenting in-
dividuals. The EMR product, which captures over one
million clinical office visits annually, is EpicCare®, (Epic
Systems, WI), and includes the reason for visit, diagnosis
codes (ICD-9-CM format), growth measurements, medi-
cations prescribed, and referrals made. The EMR is dir-
ectly interfaced with three laboratory information
systems, including one internal and two external (Quest
Diagnostics, LabCorp) lab systems. All laboratory test
results are available in a structured format, mapped to
Current Procedural Terminology (CPT) codes, and Lo-
gical Observation Identifier Names and Codes (LOINC)
as needed. All of this information is captured and moved
into our repository in a structured format for consented
research participants. We also receive radiology reports,
surgical notes, hospital discharge summaries, and Emer-
gency Department summaries and dictated specialist
reports.
Patient data is encrypted and integrated into a custom
phenotype browser, which includes all EMR, as well as
additional survey data collected at recruitment (family
history/diagnoses etc.). This allows a multidirectional
flow of de-identified phenotype information to be dir-
ectly coupled with an automated analysis pipeline, utiliz-
ing high-efficiency software tools. Only encrypted/de-
identified data reaches the phenotype browser, where it
can be coupled with genotyping, sequencing and other
data that are available on the subjects. Of the patient
DNA samples that have consented to genetic studies, we
have >99 % availability of samples available for re-
genotyping under CLIA/CAP certification or NGS, with
the ~1 % loss mainly due to small amounts of blood be-
ing obtained from the youngest children or ineffective
DNA extraction from saliva, but saliva samples consti-
tute less than 5 % of our DNA sample sets, 95 % of
which are blood-derived.
Diagnostic codes (e.g. 756.83) and keyword (e.g.
“Ehlers Danlos, EDS”) keyword searches identified a list
of 119 patients, all of which included access to lab and
diagnostic reports as described above. Patient data was
then re-identified through a reverse-encryption process,
which allowed our clinical team (who have no access to
genomic data) to conduct a complete review of the pro-
band’s entire medical chart (including medical letters)
and family medical history. Of these 119 patients, only
in the case of the identified proband did we have access
to the samples of a rather complete pedigree. For this
family we had the proband being diagnosed with EDS
and father and sister having EDS like phenotype the
mother and maternal half-brother were normal.
Proband’s medical history
The proband is currently nine years for age. He was
delivered at full term through vaginal delivery. The
birth was traumatic and forceps and suctioning were
used. His birth weight was 4.1 kg. He was diagnosed
with EDS at the age of 9 months, following admission
for joint laxity and ankle crepitus. He had slightly de-
layed development, with ambulation at approximately
14 months. At two years of age, he was referred to a
neurologist with amblyopia, who noted moderate
gross motor delay, increased shoulder girdle weakness
and central hypotonia. At 2.5 years of age, delays in
his fine motor skills and speech articulation were re-
corded. He had difficulty chewing and had weak
mouth muscles. Difficulties in fine motor skills were
recorded again at five years of age, and abnormal gait,
poor coordination, and developmental delay were
noted at multiple time points. At 9 years-of-age, he
was at the 99th percentile for both height (148.4 cm)
and weight (48.3 kg) based on the Center for Disease
Control and Prevention (CDC) weight-for-age data.
He is normocephalic, and has a fibrous anterior fon-
tanel. He has a slightly triangular face with slight
mid-face flattening. His adipose tissue in his lower
jaw and neck is decreased, and he has blue sclerae.
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He has a normal palate. He has a I/VI heart murmur
with no clicks and regular rate and rhythm.
The proband presented with a history of recurrent
joint pain and was found to have increased mobility in
his metacarpal joints, proximal and distal interphalan-
geal joints, and significant thumb hypermobility. He has
increased flexibility of his wrists, while his elbows can be
slightly hyperextended. He also has a hyperextensible
ear. He has decreased movement in his ankles, which
are also slightly contracted and unable to be dorsiflexed
beyond 900. Hypermobility improved from ages 3 to
9 years (current age), during which time he received ex-
tensive occupational and physical therapy. He does not
have any scoliosis or kyphosis. He has had two patella
dislocations, and has been admitted for fractures (distal
radius and ulna buckle) and sprain (ankle). Bone density,
however, is normal (z-score = 0.3 SD) as per dual-energy
X-ray absorptiometry (DXA) scanning at 9 years.
Other problems include urinary incontinence, ureter-
ectasis (hydroureter), and profound hydronephrosis. At
age six years, he had two posterior urethral valve surger-
ies, requiring a suprapubic tube. He has a history of anti-
body deficiency and has been receiving intravenous
immunoglobulin (IVIG) therapy every 3 weeks. He has
exotropia (his left eye drifts out) and amblyopia (com-
monly known as “lazy eye”). He is developmentally de-
layed, and a diagnosis of ADHD was recorded at 7 years
of age. EEG at 2 years of age was normal. “Components
of autism” were recorded once, at age 7.5 years. “Sensory
integration issues” were recorded once at 6 years of age.
He has decreased adipose tissue, decreased muscle mass
and hypotonia. He has a history of asthma with exacer-
bation, and reports daily fatigue. No cardiovascular ab-
normalities have been recorded. His medical history was
otherwise significant for dysphagia, recurrent vomiting
and chronic constipation.
Hitherto, no genetic anomalies have been identified.
At 2.9 years, he was screened for collagen/procollagen
abnormalities. None were detected – cells synthesized
and secreted types I and III procollagens normally,
and the efficiency of conversion of procollagen to col-
lagen, was similar to control cells. These findings
make it unlikely that he has a form of osteogenesi-
simperfecta (OI) [4–8], as cells from more than 85 %
of individuals with clinically recognizable OI have al-
terations in either the amount or the structure of
type I procollagen synthesized and typically result in
a decrease type I procollagen production by ~50 %.
OI types II (OMIM 166210), III (OMIM 259420), and
IV (OMIM 166220) are also unlikely, as they are typ-
ically caused by mutations affecting the structure of
the pro-alpha 1(I) and pro-alpha 2(I) chains of type I
procollagen, and result in substitution for glycine resi-
dues in the triple-helical domains of these chains.
These findings exclude most forms of EDS type IV,
which typically results from mutations that affect the
synthesis, structure or secretion of type III procolla-
gen. They also exclude some forms of EDS type VII
that are caused by genomics deletions that affect the
conversion of procollagen to collagen. Genetic screen-
ing tests for mutations in known EDS genes, includ-
ing TNXB and COL3A1 were also negative.
Family history
A complete pedigree (Fig. 1) is not available, but the
proband’s family history does record several details per-
tinent to this study. The proband’s sister is seven years
of age, and was last seen two years ago. There is evi-
dence of EDS with incomplete expression, with relevant
(endo) phenotypes including hypermobility, slow-healing
scars, and urinary incontinence. Ultrasound of kidney
and bladder reveal no structural abnormalities. Likewise,
cardiovascular functions appear normal, and osseous
structures are unremarkable.
We do not have direct access to the medical re-
cords of the father, but a detailed family history of
the proband reveals evidence of an EDS-type pheno-
type. The father has had multiple joint dislocations,
wounds that did not heal well, and multiple minimum
trauma fractures. He had shoulder surgery following
multiple dislocations.
The proband has a paternal uncle with suspected EDS,
including skin elasticity, and poor healing. He also has a
history of multiple shoulder dislocations and fractures
with trauma. A paternal aunt is also mentioned in the
family history, which evidences hypermobility (report-
edly able to make a “praying sign behind her back”). She
Fig. 1 Pedigree Structure of the Family with their De-Identified IDs.
Individuals with confirmed or suspected EDS are shaded. The mother
(3380), father (1966) and affected male proband (2113) had their whole
genome sequenced. For validation, affected sister (0281) and
half-brother (4736) of the proband were Sanger sequenced with
the other three family members
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also has a history of resting tremors, and poor skin heal-
ing. The proband’s paternal grandmother has several
EDS-like symptoms, including blue sclera, and joint hy-
permobility. Similar to the paternal aunt, she can make a
“praying sign behind her back.” She also has a history of
recurrent fractures (including shoulder fractures requir-
ing surgery). The proband’s mother does not have any
history of EDS-like phenotypes, although she did report
severe temporomandibular joint disorder. A maternal
half-brother has scoliosis but no other bone or joint
symptoms.
The mother (3380), father (1966) and affected male
proband (2113) had their whole genome sequenced. For
validation affected sister (0281) and half-brother (4736)
of the proband were Sanger sequenced with the other
three family members.
DNA sample collection
Blood samples from the proband, sister, maternal half-
brother and parents were collected by the Center for
Applied Genomics at Children’s hospital of Philadelphia,
with consent for prospective genomic analyses, access to
EMRs, and re-contact for further studies.
Whole genome sequencing and variant calling
Genomic DNA was isolated from the blood samples by
standard methods. Whole genome sequencing was per-
formed using Illumina®HiSeq2000 on three of the mem-
bers of family (proband and both parents) following the
manufacturer’s instructions. All raw reads were aligned
to the reference human genome build 37(UCSC hg19)
using the Burrows–Wheeler alignment [9] (BWA, 0.6.2).
Optical and PCR duplicates were marked and removed
with Picard (v.1.73). Local realignment of reads in the
indel sites and quality recalibration were performed with
the Genome Analysis Tool Kit v1.6 [10]. SNPs and small
INDELs were called with GATK UnifiedGenotyper [11].
ANNOVAR [12] and SnpEff [13] were used to annotate
the variants. Fold coverage statistics are listed in (Table 1)
and illustrated in (Fig. 2).
WGS Coverage of Proband (2113), Father (1966) and
Mother (3380). Average depth of coverage was 20–40x.
Between 86 and 99 % reached a depth of 10x.
Initial variants were filtered following GATK best prac-
tice by excluding those variants where: 1) SNPs QualBy-
Depth (QD) <2.0; 2) Root mean square (RMS) mapping
quality (MQ) <40.0; 3) Phred-scaled p-value using Fisher’s
exact test to detect strand bias (FS) > 60.0; 4) The haplo-
type score >13.0; 5) u-based z-approximation From
Mann–Whitney Rank Sum Test for mapping qualities
(MQRankSum) < −12.5; 6) ReadPosRankSum < −8.0.
Similarly, for indels, the following criteria were ap-
plied: 1) SNPs QualityByDepth (QD) <2.0; 2) Read-
PosRankSum < −20.0; 3) InbreedingCoeff < −0.8; 4)
Phred-scaled p-value using Fisher’s exact test to de-
tect strand bias in reads (FS) >200.
Variants validation through sanger sequencing
Sanger sequencing of the variants (Fig. 3) was per-
formed in order to confirm the heterozygous muta-
tion identified by the variant detection analysis (see
below). ABI 3730 sequencer with ABI BIgDye Ter-
minator Cycle Sequencing kit was used. The reference
genome sequence was obtained from UCSC Genome
browser. The PCR primers were designed for the
ADAMTSL2 mutation using the PRIMER3 (http://
bioinfo.ut.ee/primer3/) open source software. PCR was
performed using the following primers: 1) ADAMTS-
L2-forward primer sequence: CAGGAGACCAACGA-
GGTGTG; 2) ADAMTSL2-reverse primer sequence:
TGGCAGCTCTTAGGAACCTC. The resulting *. ABI
files from the sequencer were loaded into ABI Se-
quence Scanner version 1.0 for further analysis. The
sequence was manually reviewed to ensure reliability
of genotype calls.
Results
We recently identified an EDS patient, with Type VIIC
form of EDS. Our screen for mutations in ADAMTS2,
known to be associated with this sub-type and were
negative. There were no mutations in any other known
EDS-associated genes. Screenings for collagen/procolla-
gen abnormalities were also negative. The patient’s fam-
ily history includes a father and sister with EDS-like
symptoms, as well as a number of other family members
with EDS-type (endo) phenotypes. This pedigree infor-
mation suggests an inheritance pattern consistent with
autosomal dominant inheritance, possibly with variable
expressivity.
Variant-calling produced 52 candidate loci, which are
listed below. While ADAMTSL2 is the most likely source
of the EDS phenotype, one or more of these loci may be
contributing to the disease pathogenesis.
The whole genome analysis of proband (2113) yielded
3,546,583 variants. We identified about 248,772 SNV’s
that are shared by the father, proband, and not present in
the mother as we assumed it to be dominant model of
Table 1 WGS Coverage of Proband (2113), Father (1966) and
Mother (3380)
SampleID Average depth coverage % of read depth 10×
2113 40 99
1966 40 98
3380 20 86
Average depth of coverage was 20–40×. Between 86 and 99 % reached a
depth of 10×
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Fig. 2 Reads of the Proband (2113), Father (1966) and Mother (3380) Summarized as a Coverage Plot. Position and significant number of
mismatches with respect to reference are highlighted with colored bars. Individual base mismatch reads have been sorted and colored by strand
Fig. 3 Sanger Validation of the proband and family members. Graphs show Sanger genotypes of the proband (G/A), unaffected mother (G/G),
affected father (G/A), affected sister (G/A) and unaffected maternal half-brother (G/G)
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inheritance. These were analyzed for non-synonymous
mutations, which alter the amino acid sequence of a pro-
tein. We used ANNOVAR [12] for annotation of variants
and used standard variant reduction method to reduce the
number of candidate variants. As such we excluded vari-
ants that were in intronic regions, synonymous changes,
and those identified by the dbSNP131 and the 1000 Gen-
ome Project [14]. This filtering resulted in a subset of novel
non-synonymous candidate variants (Table 2). None of the
known EDS genes (Table 3) showed mutations in the pro-
band. However, manual curation and literature survey of
the 52 variants resulted in the discovery of a mutation
(c.1261G >A, p. Gly421Ser) in the ADAMTSL2 gene
(Table 4). As none of the other 52 variants resided in genes
that were putatively candidates for causing EDS, we con-
sidered the (c.1261G >A, p. Gly421Ser) variant in the
ADAMTSL2 gene to be the most likely causative source of
EDS in the family as it segregated in keeping with a
disease-causing variant in this family. This heterozygous
mutation (c.1261G >A, pGly421Ser) was detected in the
proband (2113), affected father (1966) and, affected sister
(0281). The mother (8380) and unaffected maternal half-
brother (4376) were homozygous for the wild type allele.
The mutation was confirmed by Sanger sequencing (Fig. 3).
This process is illustrated in (Fig. 4).
Mutation Characteristics SIFT Polyphen Scores and
AA Change. We identified a nonsynomous mutation
resulting in an amino acid change—G1261A—at position
13641800 on chromosome 9.
Discussion
This study illustrates the success of the research strategy
where by systematic data querying of phenotype data
from a large biorepository can be cross-referenced with
disease codes to identify the most likely cause of a rare
disease. Because we are a research/treatment hub for
children with rare disease such as EDS, our bioreposi-
tory is disproportionately enriched for phenotypes such
as these. As such, we anticipate this approach will re-
solve other rare and unidentified diseases in the future.
The A Disintegrin and Metalloproteinase with throm-
bospondin motifs (ADAMTS) family is associated with a
range of biological processes, including formation/regula-
tion of connective tissue structure, coagulation, arthritis,
angiogenesis, and cell migration [15]. The ADAMTS
superfamily includes 19 distinct members that are secreted
enzymes and at least seven ADAMTS-like proteins with-
out enzymatic activity [15–18]. The ADAMTS have two
domains – the catalytic domain at the N terminus and the
ancillary domain at their C terminus. These are required
for interaction and are distinct from A Disintegrin and Me-
talloproteinases by 1+ type I repeats. They are synthesized
as inactive zymogens, and post-translational modification
is activated by their N-terminal propeptide, which is
cleaved by furin [15]. ADAMTS-like proteins are different
from ADAMTS ancillary domains in that they are lacking
catalytic activity, due to the lack of protease domain.
Mutations in the ADAMTS family have been associ-
ated with EDS. Specifically ADAMTS2 mutations are as-
sociated with Type VIIC, which is characterized by
dermatosparaxis. This manifests in extreme skin fragility,
spontaneous ruptures of internal organs, as well as pre-
mature rupture of membranes during pregnancy [19].
Colige et al. [20] were the first to identify mutations
responsible for EDS VIIC, which were found in the
gene encoding the procollagen protease ADAMTS2,
located on chromosome 5qter (5q35.3) (originally
identified under the alias procollagen I –Proteinase).
They identified six EDS VIIC individuals, five of whom
were homozygous for a C→T transition that resulted in a
premature termination codon, Q225X, of which four were
further homozygous at three downstream polymorphic
sites (His 286 (CAT), Asp 676 (GAT), and Asp 844
(GAT)). A sixth patient was homozygous for premature
termination codon, Q225X. These are all consistent with
recessive inheritance.
Three additional mutations have been identified in the
same gene in two patients: one had a homozygous dele-
tion of exons 205, a second was compound heterozygous
for a missing exon 3 (maternal) as well as a deletion that
caused in-frame skipping of exons 14–16 [21]. This sec-
ond patient constituted the first example of compound
heterozygosity as the cause for EDS VIIC. Three more
patients from the same study had variations found in
normals, which was paralleled by silent functionality. All
five EDS VIIC patients presented with facial dys-
morphisms, hypermobility, skin and muscle fragility,
and (at least) four of were born prematurely (~32–34
weeks). Recently, a newborn with EDS VIIC was de-
scribed as presenting with congenital skull fractures
and skin lacerations [19].
Adapted from Le Goff & Cormier-Daire (2008), Rele-
vant Diseases Associated with THE ADAMTS (L) family.
Mutations in ADAMTS2 are associated EDS VIIC. A
mutation in ADAMTSL2 has previously been associated
with geleophysic dysplasia, whose phenotype includes
joint limitation
A mutation in ADAMTSL2 has previously been associ-
ated with geleophysic dysplasia (GD) [OMIM: 231050],
where the phenotype includes joint limitation. ADA-
MTSL2 encodes a secreted glycoprotein that binds the cell
surface and extracellular matrix, and interacts with latent
transforming growth factor beta binding protein 1. GD is
autosomally recessive, and can also include severe short
stature, facial dysmorphism, a ‘happy’ face, progressive
cardiac valvular thickening, respiratory insufficiency, and
lysosomal-like storage vacuoles in different tissues.
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Table 2 Variant-calling produced 52 candidate loci, which are listed below
Func Gene ExonicFunc AAChange RefSeq Conserved Genomic location (hg19) Ref Het Obs
exonic NECAP2 non NM_001145277: c.G527A: p.R176Q 336; LOD: 31 chr1:16778370 G Het A
exonic GJB4 non NM_153212: c.G371A: p.R124Q 387; LOD: 50 chr1:35227226 G Het A
exonic ZC3H12A non NM_025079: c.C95T: p.P32L chr1:37941192 C Het T
exonic HEATR8 non NM_001039464: c.T1103C: p.V368A chr1:55119702 T Het C
exonic PTGER3 non NM_198718: c.A1136G: p.Q379R chr1:71418711 T Het C
exonic SLC22A15 non NM_018420: c.G275C: p.S92T 483; LOD: 122 chr1:116534839 G Het C
exonic FLG stopgain NM_002016: c.C9740A: p.S3247X chr1:152277622 G Het T
exonic IGSF9 non NM_020789: c.G1085C: p.G362A 492; LOD: 133 chr1:159902414 C Het G
exonic PLEKHA6 non NM_014935: c.C29T: p.P10L chr1:204242827 G Het A
exonic OBSCN non NM_001098623: c.G6373T: p.A2125S chr1:228464303 G Het T
exonic RNF187 non NM_001010858: c.C535T: p.R179W 439; LOD: 81 chr1:228680805 C Het T
exonic EXO1 non NM_003686: c.G820A: p.G274R 600; LOD: 366 chr1:242023882 G Het A
exonic ITSN2 non NM_019595: c.G4580A: p.R1527H chr2:24431123 C Het T
exonic FBXO41 non NM_001080410: c.C1390T: p.R464C 609; LOD: 398 chr2:73492584 G Het A
exonic BSN non NM_003458: c.C11090T: p.P3697L 510; LOD: 158 chr3:49700681 C Het T
exonic HYAL3 non NM_001200030: c.G533A: p.R178H 325; LOD: 28 chr3:50332501 C Het T
exonic CRIPAK non NM_175918: c.C394G: p.H132D chr4:1388693 C Het G
exonic CRIPAK non NM_175918: c.C425G: p.P142R chr4:1388724 C Het G
exonic CRIPAK syn NM_175918: c.C456G: p.P152P chr4:1388755 C Het G
exonic TBC1D14 non NM_001113361: c.C538G: p.L180V 569; LOD: 274 chr4:6925654 C Het G
exonic SLC2A9 non NM_020041: c.C824T: p.T275M chr4:9922187 G Het A
exonic RAB33B non NM_031296: c.C530T: p.T177M 653; LOD: 599 chr4:140394120 C Het T
exonic FREM3 non NM_001168235: c.G1570A: p.G524R 383; LOD: 48 chr4:144620259 C Het T
exonic LOC345643 non NM_001190787: c.A361T: p.T121S 419; LOD: 67 chr5:54518800 T Het A
exonic GPR98 non NM_032119: c.T6608C: p.V2203A 657; LOD: 625 chr5:89985795 T Het C
exonic ULBP2 non NM_025217: c.C79G: p.R27G chr6:150263287 C Het G
exonic SCAF8 non NM_014892: c.T3450A: p.D1150E 678; LOD: 762 chr6:155154163 T Het A
exonic IQCE non NM_152558: c.G528C: p.E176D 476; LOD: 115 chr7:2617938 G Het C
exonic POU5F1B non NM_001159542: c.G142T: p.G48W chr8:128428253 G Het T
exonic; splicing ADAMTS13 non NM_139026: c.A3817G: p.I1273V 378; LOD: 46 chr9:136324096 A Het G
exonic ADAMTSL2 non NM_001145320: c.G1261A: p.G421S 420; LOD: 68 chr9:136419800 G Het A
exonic ARSD non NM_009589: c.C845A: p.A282D 329; LOD: 29 chrX:2835863 G Het T
exonic SLC25A5 non NM_001152: c.G413A: p.R138H 585; LOD: 319 chrX:118603925 G Het A
exonic MAGEC1 non NM_005462: c.G526C: p.V176L 358; LOD: 38 chrX:140993716 G Het C
exonic SLC4A1 non NM_000342: c.G539A: p.R180H chr17:42337247 C Het T
exonic HCN2 non NM_001194: c.G227A: p.R76H 722; LOD: 1146 chr19:590172 G Hom A
exonic; splicing UNC13A non NM_001080421: c.C3080T: p.P1027L 627; LOD: 471 chr19:17749893 G Het A
exonic ZNF780B non NM_001005851: c.C1282T: p.R428C chr19:40541484 G Het A
exonic PSG8 non NM_001130167: c.C110T: p.T37M chr19:43268388 G Het A
exonic ZC3H4 non NM_015168: c.C3326T: p.P1109L 265; LOD: 16 chr19:47570199 G Het A
exonic VSX1 stopgain NM_199425: c.C165A: p.C55X chr20:25062568 G Het T
exonic WFDC11 non NM_147197: c.T127C: p.W43R 295; LOD: 21 chr20:44278012 A Het G
exonic LOC100132288 non NM_001033515: c.C232T: p.R78C 422; LOD: 69 chr21:9909103 G Het A
exonic SERPINB4 non NM_002974: c.A193T: p.N65Y chr18:61310424 T Het A
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Le Goff et al. [22] used in situ hybridization to hu-
man fetal tissue to demonstrate ADAMTSL2 mRNA
expression in cardiomyocytes, epidermis, dermal
blood vessels, tracheal wall, skeletal muscle, pulmon-
ary arteries, and bronchioles of the lung. Strong ex-
pression was also observed in chondrocyte columns
in the hypertrophic and reserve zones of the proximal
femoral growth plate. The group used a yeast 2-
hybrid screen of a human muscle cDNA library, and
found that ADAMTSL2 bound to latent TGFβ-
binding protein-1, which is important to regulating
TGFβ availability and storing TGFβ in the extracellu-
lar matrix. While unsubstantiated by current medical
records, there is a possible relationship here with the
proband’s antibody deficiency and history of recurrent
infection.
Allali S et al.[23] recently identified 33 patients, of
whom 19 had a mutation in ADAMTSL2. The cohort
collectively shared 13 mutations. The authors com-
pared phenotypes in those that did/did not carry an
ADAMTSL2 mutation, finding that the main discrim-
inating features were facial dysmorphism and tiptoe walk-
ing. These phenotypes were absent from the proband and
his family. To our knowledge, ADAMTSL2 is not associ-
ated with any other rare disorder.
We note that Table 1 also includes a number of loci
that may also be associated with EDS and other pheno-
types reported here. Of particular interest is a heterozy-
gous non-synonymous single nucleotide variation in A
disintegrin and metalloproteinase with a thrombospon-
din type 1 motif, member 13 (ADAMTS13), which is
also known as von Willebrand factor-cleaving protease
Table 2 Variant-calling produced 52 candidate loci, which are listed below (Continued)
exonic SEZ6L2 non NM_001114099: c.G1342A: p.D448N 592; LOD: 341 chr16:29891206 C Het T
exonic EPC1 non NM_025209: c.G1384A: p.G462S 584; LOD: 314 chr10:32575629 C Het T
exonic PWWP2B non NM_138499: c.G1036A: p.E346K 243; LOD: 13 chr10:134219040 G Het A
exonic SGK223 non NM_001080826: c.C622T: p.R208C 401; LOD: 57 chr8:8235297 G Het A
exonic ATP6V0D2 non NM_152565: c.G649A: p.D217N 513; LOD: 162 chr8:87162350 G Het A
exonic ARPC1B non NM_005720: c.T1049G: p.M350R 410; LOD: 62 chr7:98991711 T Het G
exonic CUL9 non NM_015089: c.C2732T: p.P911L 463; LOD: 102 chr6:43164529 C Het T
exonic XRN1 non NM_001042604: c.A4484G: p.E1495G 622; LOD: 449 chr3:142037663 T Het C
While ADAMTSL2 is the most likely source of the EDS phenotype, one or more of these loci may be contributing to the disease pathogenesis
Table 3 Adapted from Le Goff & Cormier-Daire (2008), Relevant Diseases Associated with THE ADAMTS(L) family
Gene Function Disease Phenotype
ADAMTS2 Procollagen N propeptidase EDS VIIC Fragile skin, joint laxity
ADAMTS10 Unknown Weill-Marchesani syndrome (WMS) Short stature and extremities
Thick skin
Joint limitation
Lens dislocation
ADAMTS17 Unknown WMS-like syndrome 1 Short stature
Lens dislocation
ADAMTS13 Von Willebrand factor cleaving-protease Thrombotic thrombocytopenic purpura Capilliaries and arterioles (heart, brain, kidney)
Thrombosis of short stature and extremeties
Joint limitation
Cardiac vascular disease
ADAMTSL4 Associated with regulating deposition
of FBN1 into microfibrils
Ectopialentis Lens dislocation
ADAMTSL2 Store/regulate latent TGFB in the
extracellular matrix
EDS VIIC, Geleophysic dysplasia Hypermobility, joint laxity
Mutations in ADAMTS2 are associated EDS VIIC. A mutation in ADAMTSL2 has previously been associated with geleophysic dysplasia, whose phenotype includes
joint limitation
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(VWFCP). Although this is an exonic splicing site, it
may be of functional significance. ADAMTS13 is a zinc-
containing metalloprotease enzyme that cleaves von
Willebrand factor (vWf)—a large protein involved in
platelet adhesion and in aggregating vascular lesions.
While this demonstrates a success for data-querying of
de-identified EMR data, we stress the importance of
clinical phenotyping, which can only be accomplished
on a local level. Nevertheless, we demonstrate the utility
of unbiased large-scale recruitment and biobanking in
deciphering the genetic etiology of rare Mendelian
diseases. Families with most other Mendelian disorders
for which genetic variants have been found were biasedly
recruited by clinical experts. The majority of rare Men-
delian diseases may go unsequenced under such a re-
cruitment model. With unbiased large-scale clinical
recruitment we strive to sequence as many rare Mendel-
ian diseases as possible, and this work in uncovering a
new mutation underlying EDS serves as a successful
proof of concept to that effect.
Conclusion
Although EDS type VII has been described as an
autosomal-recessive disorder, the identification of het-
erozygous ADAMTSL2 mutations demonstrates a dom-
inant form of EDS, strictly fulfilling the diagnostic
criteria for EDS VII. Future studies delineating the spe-
cific function of the ADAMTSL2 protein will reveal how
this novel mutation and others in N-glycan-rich module
contribute to the disease phenotype.
Consent
The proband and his family members consented to re-
lease of de-identified medical and genomic information
for publication.
Table 4 Mutation characteristics SIFT polyphen scores and AA change
#Chrom Position Hg19 Reference allele Mutant allele Gene Type of mutation Amino acid change PolyPhen2 score Sift score
Chr9 13641800 G A ADAMTSL2 Nonsynonymous Gly421Ser 0.707 0.24
We identified a nonsynomous mutation resulting in an amino acid change—G1261A—at position 13641800 on chromosome 9
247882 SNV
1444 Exonic Variants 
685 Non-Synonymous
74 Genes
52 Genes ADAMTSL2 Candidate 
Gene
Gene based annotation  identifying non-synonymous 
variants for Dominant model
Removed  all the variants that are synonymous  SNV, 
stopgain SNV, stoploss SNV 
Removed all variants that are present in 1000 
genomes project
Removed all the variants that are present in 
dbSNP131
Manual curation of the 52 gene 
and literature survey 
Fig. 4 Pipeline Reduction Method for the Reduction of Variants. Manual curation identified mutations in ADAMTSL2 as the most likely cause of
the EDS phenotype
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